Japan law changes encourage dendritic venture tella
This article was originally published in Scrip
Executive Summary
A bioventure in Japan is looking to speed up the development and commercialization of immune-activating therapies for cancer through a new subsidiary and research alliance, helped by recent changes to the regulatory environment for regenerative therapies in the country. Tokyo-based tella, set up in 2004, is now looking to expedite progress with its lead dendritic cell vaccine Vaccell, which has already been administered as an experimental therapy to around 7,000 patients in Japan, in early stage clinical studies conducted through a network of academic and medical facility partners.